Form 4: Compass Therapeutics Grants CMO 1M Stock Options

Compass Therapeutics, Inc. has granted its Chief Medical Officer, Cynthia Sirard, 1,000,000 stock options as an inducement for her employment.

Summary

• Cynthia Sirard, Chief Medical Officer of Compass Therapeutics, Inc. (CMPX), was granted 1,000,000 stock options.
• The options have an exercise price of $5.17 per share.
• The grant date for these options was January 2, 2026.
• The options were issued under the Compass Therapeutics, Inc. 2025 Inducement Plan.
• This grant serves as a material inducement for Ms. Sirard's acceptance of employment with the Issuer, in accordance with Nasdaq Rule 5635(c)(4).
• The options will vest over four years: 25% on January 2, 2027, with the remaining 75% vesting in 36 substantially equal monthly installments thereafter.
• The options have an expiration date of January 2, 2036.

Sentiment

Score: 6

Explanation: The grant of stock options to a key executive is generally a positive sign for talent acquisition and retention, though it introduces potential future dilution. It's a standard practice in the industry.

Positives

• The grant of 1,000,000 stock options to the Chief Medical Officer helps attract and retain key executive talent, which is crucial for a biotechnology company like Compass Therapeutics.
• The use of an inducement plan (2025 Inducement Plan) aligns with common industry practices for executive compensation and talent acquisition.

Negatives

• The issuance of 1,000,000 stock options represents potential future dilution for existing shareholders if the options are exercised.

Future Outlook

The vesting schedule indicates a long-term commitment from the Chief Medical Officer, with options vesting over four years, aligning her incentives with the company's long-term performance.

Management Comments

• The options were granted pursuant to the Compass Therapeutics, Inc. 2025 Inducement Plan as a material inducement to the Reporting Person's acceptance of employment with the Issuer in accordance with Nasdaq Rule 5635(c)(4).

Industry Context

Inducement grants, particularly for key executive roles like Chief Medical Officer, are a standard practice in the biotechnology and pharmaceutical industries to attract and retain highly specialized talent. These grants are often substantial to compete for experienced professionals who can drive clinical development and strategic growth.

Comparison to Industry Standards

• The use of stock options as an inducement for executive employment is a common compensation strategy across the biotechnology sector, similar to practices seen at companies like Moderna or BioNTech when securing top scientific and medical leadership.
• A four-year vesting schedule, with an initial cliff and subsequent monthly vesting, is a typical structure for executive equity compensation, designed to promote long-term retention and alignment with shareholder interests, comparable to vesting schedules observed at peer companies in the clinical-stage biotech space.

Management Changes

Stakeholder Impact

• Shareholders: Potential future dilution if options are exercised, but also benefits from attracting and retaining a key executive who can drive company value.
• Employees: The grant to a senior executive can signal stability and growth opportunities within the company.

Next Steps

• The stock options will begin vesting on January 2, 2027, with subsequent monthly vesting installments over the following three years.

Key Dates

Keywords

Compass Therapeutics, CMPX, Stock Options, Executive Compensation, Chief Medical Officer, Inducement Grant, SEC Form 4, Insider Transaction, Biotechnology